Clinical Trials Logo

Solid Tumor clinical trials

View clinical trials related to Solid Tumor.

Filter by:

NCT ID: NCT02278250 Completed - Solid Tumor Clinical Trials

First in Human Study of M4344 in Participants With Advanced Solid Tumors

Start date: January 26, 2015
Phase: Phase 1
Study type: Interventional

The purpose of this study was to evaluate the safety and tolerability of multiple ascending doses of single-agent M4344 administered twice-weekly (BIW), twice daily (BID) or once daily dose schedule in participants with advanced solid tumors. This investigation is a three part study examining M4344 alone and in combination with carboplatin to determine the safety and maximum tolerated dose.

NCT ID: NCT02274610 Completed - Solid Tumor Clinical Trials

Pharmacokinetic Study of Docetaxel-PNP and Taxotere to Treat Patient With Advanced Solid Cancer

DOPNP201
Start date: November 2014
Phase: Phase 1
Study type: Interventional

Evaluation of the pharmacokinetic equivalence of two Docetaxel formulations in terms of AUC and Cmax

NCT ID: NCT02273739 Completed - Solid Tumor Clinical Trials

Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation

Start date: December 8, 2014
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety, pharmacokinetics, and clinical activity of enasidenib in adults with advanced solid tumors, including glioma, or with angioimmunoblastic T-cell lymphoma (AITL), with an isocitrate dehydrogenase-2 (IDH2) mutation.

NCT ID: NCT02264613 Completed - Lymphoma Clinical Trials

ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas

Start date: October 2014
Phase: Phase 1/Phase 2
Study type: Interventional

This study evaluates the anti-tumor effects of ALRN-6924 in patients with advanced solid tumors or lymphomas with WT TP53.

NCT ID: NCT02255292 Not yet recruiting - Solid Tumor Clinical Trials

A Study: Pure CBD as Single-agent for Solid Tumor.

Start date: November 2014
Phase: Phase 2
Study type: Interventional

Increasing lines of evidence support an antitumourigenic effect of cannabinoids, including the cannabidiol (CBD) which does not posses the psychotropic effects of D9-tetrahydrocannabinol (THC). These include anti-proliferative and pro-apoptotic effects and they are known to interfere with several mechanisms in the tumorgenesis. Yet, evidence from clinical trials among cancer patients is needed. The aim of the current study is to evaluate the impact of CBD as single treatment among cancer patients.

NCT ID: NCT02250170 Completed - Solid Tumor Clinical Trials

Safety and Biomarker of OPB-111077 in Subjects With Advanced Solid Tumor

Start date: October 23, 2014
Phase: Phase 1
Study type: Interventional

This open-label, non-randomized trial will comprise of 2 parts. A dose escalation part will characterize the safety, biomarker and pharmacokinetics of OPB-111077 in advanced solid tumor. Subsequently, an expansion part will further evaluate the biomarker, safety, pharmacokinetics and antitumor activity of OPB-111077 in selected tumor types.

NCT ID: NCT02250157 Completed - Solid Tumor Clinical Trials

A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced Malignancies

Start date: September 5, 2014
Phase: Phase 1
Study type: Interventional

This study a nonrandomized, open-label, uncontrolled, single group assignment, safety and activity study in subjects with histologically or cytologically confirmed solid tumor that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective.

NCT ID: NCT02232243 Completed - Solid Tumor Clinical Trials

HCQ on PAR-4 Levels in Patients With Resectable Solid Tumors

Start date: July 2015
Phase: Phase 1
Study type: Interventional

Baseline levels of PAR-4 secreted by normal cells are generally inadequate to cause massive apoptosis in cancer cells and drugs that bolster the secretion of PAR-4 would constitute an important therapeutic advance.The apoptosis sensitizing features of hydroxychloroquine enhance the anti-tumor effects of a broad range of cancer therapeutics. The investigators hypothesize that hydroxychloroquine will induce at least 2-fold increase in systemic (plasma) PAR-4 levels compared to pre-treatment plasma levels in patients with resectable solid tumors.

NCT ID: NCT02220556 Recruiting - Solid Tumor. Clinical Trials

Evaluation of Different Analysis Methods for Circulating Tumor Cells, Circulating Endothelial Cell, and Circulating Tumor DNA in Patient Followed for a Tumoral Pathology

CTC-CEC-ADN
Start date: December 2010
Phase: N/A
Study type: Interventional

Fifteen cohorts will be opened. Each cohort will explore one analysis method and/or tumoral type. Up to 50 patient can be included into each cohort.

NCT ID: NCT02216409 Completed - Solid Tumor Clinical Trials

Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody

Start date: August 2014
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety and tolerability of Hu5F9-G4 in participants with solid tumors.